JP2007535552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535552A5 JP2007535552A5 JP2007510974A JP2007510974A JP2007535552A5 JP 2007535552 A5 JP2007535552 A5 JP 2007535552A5 JP 2007510974 A JP2007510974 A JP 2007510974A JP 2007510974 A JP2007510974 A JP 2007510974A JP 2007535552 A5 JP2007535552 A5 JP 2007535552A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- retinal
- disease
- receptor agonist
- adrenergic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 claims description 89
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 46
- 229920002988 biodegradable polymer Polymers 0.000 claims description 29
- 239000004621 biodegradable polymer Substances 0.000 claims description 29
- 208000017442 Retinal disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 208000024891 symptom Diseases 0.000 claims description 16
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 229960003679 brimonidine Drugs 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 230000002207 retinal effect Effects 0.000 claims description 11
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 11
- 206010046851 Uveitis Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 230000004304 visual acuity Effects 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 208000031886 HIV Infections Diseases 0.000 claims description 9
- 208000037357 HIV infectious disease Diseases 0.000 claims description 9
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 9
- 206010038923 Retinopathy Diseases 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 208000001344 Macular Edema Diseases 0.000 claims description 7
- 206010025415 Macular oedema Diseases 0.000 claims description 7
- 206010038848 Retinal detachment Diseases 0.000 claims description 7
- 201000010230 macular retinal edema Diseases 0.000 claims description 7
- 210000001927 retinal artery Anatomy 0.000 claims description 7
- 230000004264 retinal detachment Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000002367 Retinal Perforations Diseases 0.000 claims description 6
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 210000001525 retina Anatomy 0.000 claims description 6
- 208000006379 syphilis Diseases 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 5
- 208000027129 choroid disease Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
- 229960001724 brimonidine tartrate Drugs 0.000 claims description 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 4
- 201000011190 diabetic macular edema Diseases 0.000 claims description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims description 3
- 208000014882 Carotid artery disease Diseases 0.000 claims description 3
- 208000016623 Choroid neoplasm Diseases 0.000 claims description 3
- 206010070957 Choroidal haemangioma Diseases 0.000 claims description 3
- 208000002691 Choroiditis Diseases 0.000 claims description 3
- 208000021089 Coats disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010011732 Cyst Diseases 0.000 claims description 3
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000002927 Hamartoma Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 241000228402 Histoplasma Species 0.000 claims description 3
- 201000002563 Histoplasmosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 206010058558 Hypoperfusion Diseases 0.000 claims description 3
- 206010022557 Intermediate uveitis Diseases 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 208000009857 Microaneurysm Diseases 0.000 claims description 3
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims description 3
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 3
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims description 3
- 208000034247 Pattern dystrophy Diseases 0.000 claims description 3
- 208000003971 Posterior uveitis Diseases 0.000 claims description 3
- 206010064714 Radiation retinopathy Diseases 0.000 claims description 3
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims description 3
- 206010038897 Retinal tear Diseases 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 206010038915 Retinitis viral Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 3
- 206010039705 Scleritis Diseases 0.000 claims description 3
- 206010040925 Skin striae Diseases 0.000 claims description 3
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims description 3
- 208000027073 Stargardt disease Diseases 0.000 claims description 3
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 3
- 206010044269 Toxocariasis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000029977 White Dot Syndromes Diseases 0.000 claims description 3
- 210000001766 X chromosome Anatomy 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 230000009852 coagulant defect Effects 0.000 claims description 3
- 201000008615 cone dystrophy Diseases 0.000 claims description 3
- 208000006623 congenital stationary night blindness Diseases 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 210000004177 elastic tissue Anatomy 0.000 claims description 3
- 206010014801 endophthalmitis Diseases 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 230000001631 hypertensive effect Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 3
- 208000038015 macular disease Diseases 0.000 claims description 3
- 208000029233 macular holes Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 208000008940 ocular tuberculosis Diseases 0.000 claims description 3
- 208000008798 osteoma Diseases 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 230000000649 photocoagulation Effects 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 201000004849 posterior scleritis Diseases 0.000 claims description 3
- 201000002267 posterior uveal melanoma Diseases 0.000 claims description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000009897 systematic effect Effects 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 3
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims description 2
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 claims description 2
- 208000014087 Chorioretinal disease Diseases 0.000 claims description 2
- 206010065119 Necrotising herpetic retinopathy Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010038899 Retinal telangiectasia Diseases 0.000 claims description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 2
- 230000001174 ascending effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 201000005849 central retinal artery occlusion Diseases 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 230000004377 improving vision Effects 0.000 claims description 2
- 201000002165 neuroretinitis Diseases 0.000 claims description 2
- 239000000790 retinal pigment Substances 0.000 claims description 2
- 201000007714 retinoschisis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 19
- 239000011159 matrix material Substances 0.000 claims 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims 17
- 229940127557 pharmaceutical product Drugs 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 14
- 229920000642 polymer Polymers 0.000 claims 13
- 150000003252 quinoxalines Chemical group 0.000 claims 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000004626 polylactic acid Substances 0.000 claims 4
- 230000004438 eyesight Effects 0.000 claims 3
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 2
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 2
- 206010053648 Vascular occlusion Diseases 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 2
- 201000002588 choroid cancer Diseases 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 208000033379 Chorioretinopathy Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000006123 Myiasis Diseases 0.000 claims 1
- 206010064997 Necrotising retinitis Diseases 0.000 claims 1
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 3
- QZHBYNSSDLTCRG-LREBCSMRSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 QZHBYNSSDLTCRG-LREBCSMRSA-N 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/836,911 US20050244463A1 (en) | 2004-04-30 | 2004-04-30 | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| PCT/US2005/014607 WO2005110368A1 (en) | 2004-04-30 | 2005-04-26 | Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012228958A Division JP5696121B2 (ja) | 2004-04-30 | 2012-10-16 | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535552A JP2007535552A (ja) | 2007-12-06 |
| JP2007535552A5 true JP2007535552A5 (enExample) | 2008-06-19 |
Family
ID=34967610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510974A Pending JP2007535552A (ja) | 2004-04-30 | 2005-04-26 | α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法 |
| JP2012228958A Expired - Fee Related JP5696121B2 (ja) | 2004-04-30 | 2012-10-16 | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012228958A Expired - Fee Related JP5696121B2 (ja) | 2004-04-30 | 2012-10-16 | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US20050244463A1 (enExample) |
| EP (2) | EP2305261B1 (enExample) |
| JP (2) | JP2007535552A (enExample) |
| KR (1) | KR20070064415A (enExample) |
| CN (1) | CN1950067A (enExample) |
| AT (1) | ATE516033T1 (enExample) |
| AU (2) | AU2005244149A1 (enExample) |
| BR (1) | BRPI0510504A (enExample) |
| CA (1) | CA2565067C (enExample) |
| DK (1) | DK1758552T3 (enExample) |
| ES (1) | ES2367804T3 (enExample) |
| MX (1) | MXPA06012291A (enExample) |
| NZ (1) | NZ550009A (enExample) |
| WO (1) | WO2005110368A1 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| BRPI0506983A (pt) | 2004-01-20 | 2007-07-03 | Allergan Inc | composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico |
| US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2006094014A2 (en) | 2005-02-28 | 2006-09-08 | The Regents Of The University Of California | Methods for diagnosis and treatment of endometrial cancer |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| EP1924292A2 (en) | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| ITMI20061538A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
| EP2178502A2 (en) * | 2007-06-21 | 2010-04-28 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
| US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US12246013B2 (en) | 2008-08-01 | 2025-03-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| US8580787B2 (en) | 2008-08-01 | 2013-11-12 | Eye Therapies Llc | Compositions and methods for reducing activation of alpha-1 receptors |
| HRP20180738T1 (hr) | 2008-09-15 | 2018-06-15 | F. Hoffmann - La Roche Ag | Pripravci i postupci za regulaciju stanične osmolarnosti |
| US20100098772A1 (en) * | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| JP2012515791A (ja) * | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ， インコーポレイテッド | ポリマー混成物由来の放出制御システム |
| US8617583B2 (en) * | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
| US20110097375A1 (en) * | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
| CA2779104C (en) * | 2009-10-30 | 2018-07-17 | Aton Pharma, Inc. | Ocular drug delivery devices |
| DK2498783T3 (en) | 2009-11-09 | 2018-12-10 | Allergan Inc | COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH |
| JP5911805B2 (ja) | 2009-11-20 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ） |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| TW201141477A (en) * | 2010-01-21 | 2011-12-01 | Allergan Inc | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| CA2790500A1 (en) | 2010-02-19 | 2011-08-25 | Lynn K. Gordon | Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
| JP5747392B2 (ja) * | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物 |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| CN106214321B (zh) | 2010-10-15 | 2018-08-28 | 科尼尔赛德生物医学公司 | 用于进入眼睛的装置 |
| SG10201910521YA (en) | 2010-11-16 | 2020-01-30 | Allergan Inc | Pharmaceutical Compositions Comprising (3-(1-(1H-Imidazol-4-yl)Ethyl)-2-Methylphenyl) Methanol |
| CN103429266A (zh) * | 2010-11-26 | 2013-12-04 | 约翰内斯堡金山大学 | 药物递送装置 |
| US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
| JP6223963B2 (ja) | 2011-05-18 | 2017-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 網膜疾患を処置するための組成物および方法 |
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| US20150044148A1 (en) * | 2011-10-19 | 2015-02-12 | Galderma Laboratories, Inc. | Method for Treating Capillary Hemangiomas |
| EP2782569A1 (en) | 2011-11-21 | 2014-10-01 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| RU2014125518A (ru) | 2011-11-28 | 2016-02-10 | Аллерган, Инк. | Фармацевтические композиции, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидро-хинолин для ретинальной нейропротекции |
| BR112014020127A2 (pt) | 2012-02-14 | 2020-06-30 | The Regents Of The University Of Calefornia | métodos para tratamento, melhoramento ou proteção (prevenção) de um indivíduo ou um paciente, e de uma disfunção, uma doença, uma infecção ou uma condição, e, método para suprimir o ganho de peso, ou suprimir o apepite, ou estimular ou iniciar a perda de peso |
| EA034963B1 (ru) | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Способ лечения расстройства заднего сегмента глаза |
| RU2641021C2 (ru) * | 2013-02-15 | 2018-01-17 | Аллерган, Инк. | Имплантат для пролонгированной доставки лекарственного средства |
| WO2014159576A1 (en) | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| CN105246529B (zh) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | 用于眼部注射的设备和方法 |
| WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
| EP3351239B1 (en) | 2013-10-31 | 2020-04-01 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| AU2015242354A1 (en) | 2014-04-03 | 2016-11-10 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure |
| EP3157598A4 (en) | 2014-06-20 | 2018-05-16 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
| KR102630754B1 (ko) | 2015-03-16 | 2024-01-26 | 매직 립, 인코포레이티드 | 증강 현실 펄스 옥시미트리 |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| CN105935442A (zh) * | 2016-01-08 | 2016-09-14 | 新昌县大成生物科技有限公司 | 一种治疗青光眼的药物组合物 |
| CA3019946C (en) | 2016-04-08 | 2023-02-28 | Magic Leap, Inc. | Augmented reality systems and methods with variable focus lens elements |
| JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル，インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
| CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
| CA3052831A1 (en) | 2017-02-23 | 2018-08-30 | Magic Leap, Inc. | Variable-focus virtual image devices based on polarization conversion |
| WO2018175922A1 (en) * | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| US12090294B2 (en) | 2017-05-02 | 2024-09-17 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| CN111201040A (zh) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
| JP7350314B2 (ja) | 2017-06-05 | 2023-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 網膜疾患を処置するための組成物ならびにそれを作製および使用するための方法 |
| KR20210047323A (ko) * | 2018-08-21 | 2021-04-29 | 알러간, 인코포레이티드 | 시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도 |
| EP3990042A4 (en) | 2019-06-27 | 2023-07-19 | Layerbio, Inc. | METHODS AND SYSTEMS FOR RELEASING EYE DEVICES |
| EP4661868A1 (en) * | 2023-02-08 | 2025-12-17 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
| CN117571883B (zh) * | 2024-01-15 | 2024-03-19 | 四川智强医药科技开发有限公司 | 一种酒石酸溴莫尼定滴眼液的质量检测方法 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2194704A (en) | 1938-04-15 | 1940-03-26 | Du Pont | Unsaturated ketones and process for producing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| SE390255B (sv) * | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US3966749A (en) * | 1975-02-10 | 1976-06-29 | Interx Research Corporation | Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4052505A (en) * | 1975-05-30 | 1977-10-04 | Alza Corporation | Ocular therapeutic system manufactured from copolymer |
| US4057619A (en) | 1975-06-30 | 1977-11-08 | Alza Corporation | Ocular therapeutic system with selected membranes for administering ophthalmic drug |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4190642A (en) * | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4303637A (en) | 1980-04-04 | 1981-12-01 | Alza Corporation | Medication indicated for ocular hypertension |
| US4281654A (en) * | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4396625A (en) * | 1980-05-13 | 1983-08-02 | Sumitomo Chemical Company, Limited | Treatment of glaucoma or ocular hypertension and ophthalmic composition |
| US4425346A (en) * | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4494247A (en) * | 1981-12-28 | 1985-01-22 | Trace Athletic Corporation | Knee/elbow guard treated to increase durability and a process for producing same |
| JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| DE3220156C2 (de) * | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4693885A (en) * | 1984-07-18 | 1987-09-15 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4935495A (en) * | 1984-12-21 | 1990-06-19 | Oncogen | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas |
| FR2577509B1 (fr) | 1985-02-21 | 1987-05-07 | Nirvana Espar Systems Sa | Mat de bateau a voile |
| US4656186A (en) * | 1985-04-30 | 1987-04-07 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US4981871A (en) * | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
| DE3734223A1 (de) | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US5190966A (en) * | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US5198460A (en) * | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5093349A (en) * | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| ES2062102T5 (es) | 1988-09-06 | 2004-12-01 | Pharmacia Ab | Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular. |
| US4935498A (en) | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5268178A (en) | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
| US5503721A (en) * | 1991-07-18 | 1996-04-02 | Hri Research, Inc. | Method for photoactivation |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5075115A (en) | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
| US5232844A (en) * | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| US5100431A (en) * | 1990-09-27 | 1992-03-31 | Allergan, Inc. | Single stitch suture needle and method |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| MX9203083A (es) * | 1991-06-21 | 1994-08-31 | Genetics Inst | Formulaciones farmaceuticas de proteinas osteogenicas. |
| US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| IT1263116B (it) | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
| US5655832A (en) * | 1992-04-16 | 1997-08-12 | Tir Technologies, Inc. | Multiple wavelength light processor |
| US5244914A (en) * | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6217869B1 (en) * | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| JP3000187B2 (ja) * | 1993-02-26 | 2000-01-17 | 参天製薬株式会社 | 生体分解性強膜プラグ |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| DE4403326C1 (de) * | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6270492B1 (en) * | 1994-09-09 | 2001-08-07 | Cardiofocus, Inc. | Phototherapeutic apparatus with diffusive tip assembly |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| HUP9700322A3 (en) | 1995-06-09 | 2001-03-28 | Euro Celtique Sa | Formulations and methods for providing prolonged local anesthesia |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5856329A (en) | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| US5906920A (en) * | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5827072A (en) * | 1996-02-21 | 1998-10-27 | Neufer; David J. | Graphic, sports-related instruction board |
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| GB9616672D0 (en) * | 1996-08-08 | 1996-09-25 | Scherer Ltd R P | Pharmaceutical compositions |
| AU4582797A (en) * | 1996-09-13 | 1998-04-02 | Regents Of The University Of California, The | Methods for treatment of retinal diseases |
| US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
| US6270749B1 (en) * | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
| US6274614B1 (en) * | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| EP0994709A4 (en) * | 1997-06-30 | 2006-02-01 | Allergan Inc | CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY |
| WO1999001156A1 (en) * | 1997-07-02 | 1999-01-14 | Santen Pharmaceutical Co., Ltd. | Polylactic acid scleral plugs |
| JPH1170138A (ja) * | 1997-07-02 | 1999-03-16 | Santen Pharmaceut Co Ltd | ポリ乳酸強膜プラグ |
| US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| EP1003569B1 (en) * | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
| US6271220B1 (en) * | 1998-03-11 | 2001-08-07 | Allergan Sales, Inc. | Anti-angiogenic agents |
| ATE428345T1 (de) | 1998-07-09 | 2009-05-15 | Curelight Medical Ltd | Vorrichtung und verfahren zur wirkungsvollen hochenergetischen photodynamischen therapie von akne vulgaris und seborrhoe |
| EP1130996B1 (en) | 1998-11-20 | 2005-04-13 | The University of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
| US6410045B1 (en) | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
| US6317616B1 (en) | 1999-09-15 | 2001-11-13 | Neil David Glossop | Method and system to facilitate image guided surgery |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6319273B1 (en) | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| US20010049369A1 (en) | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| EP1997513B1 (en) | 2000-02-10 | 2012-04-11 | Massachusetts Eye & Ear Infirmary | Combinations and compositions for use in PDT in treating ocular conditions involving unwanted choriodal neovascularisation |
| EP1263434A1 (en) | 2000-03-17 | 2002-12-11 | Alcon, Inc | Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma |
| US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| CN100569291C (zh) * | 2000-07-14 | 2009-12-16 | 阿勒根公司 | 含有α-2肾上腺素能激动剂的组合物 |
| US6357568B1 (en) * | 2000-09-27 | 2002-03-19 | Shou Mao Chen | Structure for protecting a luggage shell |
| AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| ATE306951T1 (de) * | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
| US6595945B2 (en) * | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US7563255B2 (en) * | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| TWI298257B (en) * | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US6713268B2 (en) | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| WO2003027102A1 (en) * | 2001-09-27 | 2003-04-03 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| WO2003041685A1 (en) | 2001-11-14 | 2003-05-22 | Alza Corporation | Injectable depot composition |
| PT1487498E (pt) * | 2002-03-18 | 2009-08-19 | Novartis Ag | Formulação tópica contendo um ciclofrutano, um veículo e um fármaco |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| MXPA05000632A (es) * | 2002-07-15 | 2005-03-31 | Alcon Inc | Composiciones para implante farmaceuticas, lipofilas, no polimericas para uso intraocular. |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| US7468065B2 (en) | 2002-09-18 | 2008-12-23 | Allergan, Inc. | Apparatus for delivery of ocular implants |
| WO2004043432A2 (en) * | 2002-11-06 | 2004-05-27 | Alza Corporation | Controlled release depot formulations |
| ATE440595T1 (de) * | 2003-01-24 | 2009-09-15 | Psivida Inc | Vorrichtung mit verlängerter freisetzung und verfahren zur okularen verabreichung von adrenergen wirkstoffen |
| US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US7247836B2 (en) * | 2004-12-16 | 2007-07-24 | Micron Technology, Inc. | Method and system for determining motion based on difference image correlation |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
-
2004
- 2004-04-30 US US10/836,911 patent/US20050244463A1/en not_active Abandoned
-
2005
- 2005-04-26 NZ NZ550009A patent/NZ550009A/en not_active IP Right Cessation
- 2005-04-26 AT AT05741206T patent/ATE516033T1/de not_active IP Right Cessation
- 2005-04-26 BR BRPI0510504-8A patent/BRPI0510504A/pt not_active Application Discontinuation
- 2005-04-26 EP EP10184295.3A patent/EP2305261B1/en not_active Expired - Lifetime
- 2005-04-26 WO PCT/US2005/014607 patent/WO2005110368A1/en not_active Ceased
- 2005-04-26 DK DK05741206.6T patent/DK1758552T3/da active
- 2005-04-26 JP JP2007510974A patent/JP2007535552A/ja active Pending
- 2005-04-26 KR KR1020067022639A patent/KR20070064415A/ko not_active Abandoned
- 2005-04-26 EP EP05741206A patent/EP1758552B1/en not_active Expired - Lifetime
- 2005-04-26 CA CA2565067A patent/CA2565067C/en not_active Expired - Fee Related
- 2005-04-26 AU AU2005244149A patent/AU2005244149A1/en not_active Abandoned
- 2005-04-26 MX MXPA06012291A patent/MXPA06012291A/es active IP Right Grant
- 2005-04-26 CN CNA2005800135737A patent/CN1950067A/zh active Pending
- 2005-04-26 ES ES05741206T patent/ES2367804T3/es not_active Expired - Lifetime
- 2005-04-29 US US11/119,021 patent/US8293741B2/en active Active
-
2008
- 2008-01-31 US US12/024,010 patent/US9161938B2/en active Active
- 2008-01-31 US US12/024,017 patent/US8580292B2/en not_active Expired - Fee Related
- 2008-01-31 US US12/024,014 patent/US8506986B2/en not_active Expired - Fee Related
-
2011
- 2011-05-12 AU AU2011202200A patent/AU2011202200B2/en not_active Ceased
-
2012
- 2012-10-16 JP JP2012228958A patent/JP5696121B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-19 US US14/886,376 patent/US10201641B2/en not_active Expired - Lifetime
-
2019
- 2019-02-11 US US16/272,508 patent/US20190167858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535552A5 (enExample) | ||
| JP6700348B2 (ja) | 持続型薬物送達インプラント | |
| JP7519413B2 (ja) | 眼科用薬剤組成物、眼科用キット、及びその医学的応用 | |
| JP5485314B2 (ja) | ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント | |
| RU2664686C2 (ru) | Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением | |
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| AU2014350095B2 (en) | Eye device | |
| JP2007535539A (ja) | β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラントおよび眼の神経障害の治療方法 | |
| CN107184544A (zh) | 前房内持续释放治疗药植入物 | |
| WO2014066658A1 (en) | Ketorolac-containing sustained release drug delivery systems | |
| CN111358751B (zh) | 眼用药物组合物、眼用药盒及其医药用途 | |
| CN111358750B (zh) | 一种眼用药物组合物及其医药用途 | |
| HK40074896A (en) | Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof | |
| HK40064642A (en) | Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof | |
| HK40064642B (zh) | 一种眼用药物组合物、眼用药盒及其医药应用 |